Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy.
暂无分享,去创建一个
C H Fox | H. Schuitemaker | C. Fox | I. T. Ten Berge | J. Goudsmit | R. V. van Rij | F. de Wolf | S. Yong | S. Jurriaans | J. Prins | M. Roos | J. Lange | P. Schellekens | J. Lange | J Goudsmit | F de Wolf | J M Lange | H. Blaak | M T Roos | P T Schellekens | S Jurriaans | H Schuitemaker | J M Prins | R M van Praag | H Blaak | R van Rij | I J ten Berge | S L Yong | J. Prins | R. V. van Praag | I. T. ten Berge | M. Th. L. Roos | J. Goudsmit | M. Roos
[1] E. Reinherz,et al. Triggering of the T3-Ti antigen-receptor complex results in clonal T-cell proliferation through an interleukin 2-dependent autocrine pathway. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[2] L. Chatenoud,et al. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. , 1986, Journal of immunology.
[3] M. Suthanthiran,et al. Effect of immunosuppressants on OKT3 associated T cell activation: clinical implications. , 1987, Kidney international.
[4] A. Gaber,et al. Complications and monitoring of OKT3 therapy. , 1988, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[5] J. Bluestone,et al. In vivo administration of anti-CD3 prevents malignant progressor tumor growth. , 1988, Science.
[6] D. Feinfeld,et al. Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. Bluestone,et al. Activation of human T cells in vivo following treatment of transplant recipients with OKT3. , 1990, Transplantation.
[8] C. Ferran,et al. IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATION: SYSTEMIC CYTOKINE RELEASE AND MODULATION BY CORTICOSTEROIDS , 1990, Transplantation.
[9] D. Green,et al. Activation-induced apoptosis in lymphocytes. , 1994, Current opinion in immunology.
[10] C. Fox,et al. HIV in infected lymph nodes , 1994, Nature.
[11] Robert F. Siliciano,et al. In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency , 1995, Nature Medicine.
[12] M. van Buchem,et al. Reversible neurotoxicity during interleukin-2 therapy for metastatic renal cell carcinoma. , 1995, European Journal of Cancer.
[13] B. Memoli,et al. Interleukin-2-induced renal dysfunction in cancer patients is reversed by low-dose dopamine infusion. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[14] C. Ferran,et al. In vivo anti-CD3-driven cell activation. Cellular source of induced tumor necrosis factor, interleukin-1 beta, and interleukin-6. , 1996, Transplantation.
[15] H. Schuitemaker,et al. Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. , 1996, The Journal of infectious diseases.
[16] J. Metcalf,et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. , 1996, The New England journal of medicine.
[17] R Brookmeyer,et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.
[18] D. Richman,et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.
[19] J. Metcalf,et al. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. , 1997, The Journal of infectious diseases.
[20] P. Harrigan,et al. Prospective longitudinal analysis of viral load and surrogate markers in relation to clinical progression in HIV type 1-infected persons. , 1997, AIDS research and human retroviruses.
[21] R. Siliciano,et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.
[22] I. T. Ten Berge,et al. Administration of OKT3 as a two-hour infusion attenuates first-dose side effects. , 1997, Transplantation.
[23] H. Schuitemaker,et al. Alternative multidrug regimen provides improved suppression of HIV‐1 replication over triple therapy , 1998, AIDS.
[24] D. Ho,et al. Toward HIV eradication or remission: the tasks ahead. , 1998, Science.
[25] J. Smeitink,et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway , 1998, AIDS.
[26] David A. Cooper,et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.
[27] Anthony S. Fauci,et al. Induction of HIV-1 Replication in Latently Infected CD4+ T Cells Using a Combination of Cytokines , 1998, The Journal of experimental medicine.
[28] J. Lisziewicz,et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.